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Morphologic Features of the Ductus Arteriosus After Prostaglandin E1
Administration for Ductus-Dependent Congenital Heart Defects
IN-SOaK PARK, MD, MICHAEL R. NIHILL, MD, FACC, JACK L. TITUS, MD, PhD
Houston, Texas
Histologic evidence of damage to the ductus arteriosus
after the infusion of prostaglandin E. has been reported
in neonates with ductus-dependent congenital heart de-
fects. The reported changes suggested structural weak-
ening of the ductus that might render it prone to lac-
eration or rupture. The morphologic features of ductus
arteriosi were studied in two groups of neonates with
ductus-dependent congenital heart defects. Group 1
(prostaglandin E. group) comprised 12 neonates who re-
ceived prostaglandin E. and died while receiving it or
within 4 days after its administration was discontinued;
the mean duration of prostaglandin E, administration
was 18 hours (range 30 minutes to 40 hours). Group 2
(control group) comprised 10neonates whodid not receive
prostaglandin E. and were matched with group 1 for
weight, type of congenital heart defect and age at death.
The length of the ductus and its internal diameter at
the aortic end were greater in group I than in group 2,
but the differences were not statistically significant. The
internal diameter of the ductus at the pulmonary end
was significantly greater in group I than in group 2 (p
<0.05). Histologic staging of maturation of the ductus
Prostaglandin E I has been used with increasing frequency
in neonates with ductus-dependent congenital heart defects
since its use in human neonates with cyanotic congenital
heart malformations was reported by Elliott et a!' (I) and
Olley et a!. (2). Prostaglandin E I has proved to be valuable
for the emergency treatment of neonates with severe con-
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(stage 1 being most immature and stage 4 being most
mature or functionally closed) showed that the ductus
arteriosi of group I were significantly more immature
than those of group 2. Maturational stage averaged 1.67
± 0.30 (mean ± standard error of the mean) in group
I and 3.00 ± 0.29 in group 2 (p <0.0025). Histopath-
ologic abnormalities reported by other investigators were
found in only two patients from each group.
Cineangiograms obtained at the repeat cardiac cath-
eterization up to 33 months after prostaglandin E. treat-
ment in 28 infants showed no abnormality at the ductus
area; in all but I infant, the ductus either spontaneously
closed or had been surgically ligated uneventfully. In an
additional 33 patients, clinical follow-up did not suggest
any problems in the ductus. It is concluded that the
administration of prostaglandin E. may delay the normal
closing process or maturation of the ductus but does not
have any significant deleterious morphologic or clinical
effect, and that the ductus arteriosus closes normally
after prostaglandin E, is discontinued. Prolonged
administration of prostaglandin E. (more than 40 hours)
may cause the histologic changes observed by others.
genital heart defects where pulmonary or systemic blood
flow depends on the patency of the ductus arteriosus (3-7),
and in other types of congenital heart disease, such as coarc-
tation of the aorta (8), transposition of the great arteries (9-
II) and Ebstein's anomaly (12). Three recent reports (12-
14) described histologic abnormalities of the ductus arter-
iosus after prostaglandin E I administration that might have
significant deleterious effects on the structural integrity of
the ductus. In view of these observations. it has been advised
to administer prostaglandin E1 only in a low dose and for
as short a time as possible. Follow-up angiograms of the
ductus in infants after infusion of prostaglandin E 1 in the
neonatal period have not been reported. In this report, we
describe the histopathologic and angiographic features of
the ductus arteriosus after prostaglandin E1 administration.
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Table 1. Summary of Data From Prostaglandin EI (PGE I ) Group
PGE, Therapy Time From
Discontinuation
Age at of PGE, Cause Stage Morphology
Duration Death to Death of of of
Case Diagnosis (h) Response Route Operation (days) (days) Death DA DA
I P Atr, IVS 12.3 ++ Ao Shunt 6 3 Sepsis Medial edema
2 P Atr, IVS 18 ++ Ao Shunt 4 2 Sepsis Medial edema
3 P Atr, asplenia 2.5 ++ Ao Shunt 15/24 0 Postop Medial edema
4 P Atr, asplerna 40 ++ Ao 6 3 Hypoxia Normal
5 Severe PS, IVS 37.5 ++ Ao Valv 2 0 Postop Medial Hem
6 T Atr, PS 0.5 LV Shunt 17 4 Sepsis Medial Hem,
thrombus
7 TGA,IVS 37 P-V B-H 6 0 Hypoxia 2 Medial edema
8 TGA, IVS, TI 21 + Ao 3 0 Hypoxia 4 Medial edema
9 TGA,IVS 0.5 Ao I 0 Hypoxia 2 Normal
10 IAA 18.5 + Ao Repair 3 05 Postop 3a Medial edema
II M + Ao Atr 9 ++ RA 2 0 Low CO 2 Normal
12 M + Ao Atr 47 P-V 6 0 Low CO I Normal
Ao = aorta at level of theductus; B-H = Blalock-Hanlon procedure. CO = cardiac output; DA = ductus artenosuv, Hem = hemorrhage. fAA = Interrupted aornc
arch; IVS = Intact ventncular septum, LV = left ventricle: M + Ao Atr = mitral plus aornc atresia: Medial Hem = medial hemorrhage. P Atr = pulmonary atresia. Po-top
= postoperative death; PS = pulmonary stenosis: P-V = penpheral vein, RA = right atnum: Shunt = systemic to pulmonary shunt, T Atr = tncuspid atresia, TGA =
transposition ofthegreat artenes; TI = tricuspid insufficiency. Valv = pulmonary valvotomy. + = shght Improvement. + + = marked Improvement. - = noImprovement
Methods
Studypatients. Prostaglandin E 1 was administered to 70 neo-
nates with congenital heart defects during the 3.5 year period from
January 1977 to June 1980 at Texas Children's Hospital. Twenty-
one of these 70 neonates died within 20 days of life, 13 died after
20 days of life and 36 were alive in December 1980. Of the 21
patients who died within 20 days of life, complete heart specimens
were available for morphologic examination from 12 patients (pro-
staglandin E, group, n= 12, Table I). Cardiac specimens from 10
neonates whose cardiac diagnosis, age at death, body weight and
sex were similar to those in the prostaglandin E , group were selected
for comparative study of the ductus artenosus (control group,
n = 10, Table 2). The neonates in the control group were born
before January 1977 when prostaglandin E 1 first became available
Table 2. Summary of Data From Control Group
for human use in this hospital. All neonates in both groups were
term infants.
In the prostaglandin £1 group. infusions began at a mean age
of 2 days (range 12 hours to 13 days) and were continued for a
mean duration of 18 hours (range 30 mmutes to 40 hours). In
almost all patients, the dose of prostaglandin E1 was 0.1 JLg/kgper
min initially, with a subsequent decrease to the lowest effective
dose, Six of 12 neonates responded favorably to prostaglandin E I
therapy and showed marked improvement; 2 showed slight im-
provement and 4 showed no improvement. Marked improvement
was considered to be an increase in arterial oxygen saturation of
greater than 20% in babies with right heart obstructive lesions,
and an improved perfusion and blood pressure m babies with left
heart obstructive lesions.
Case Diagnosis
I P Atr, IVS
2 P Atr, IVS
3 P Atr, IVS
4 TGA
5 IAA
6 IAA
7 CoA
8 CoA, L-TGA
9 M + Ao Atr
10 Severe AS + MS
Operation
Shunt
Shunt, Valv
Repair
Age at Cause Stage Morphology
Death of of of
(day) Death DA DA
14 Postop 2 Normal
3 Postop 3 Normal
12 Hypoxia 3a Normal
7 Hypoxia 4 Medial edema
2 Low CO 3 Medial edema,
medial Hem
3 Postop 3a Advenlltia Hem
5 CHF 2 Normal
9 Low CO 3 Normal
3 Low CO 3 Normal
12 Low CO 4 Medial edema
AS = aortic stenosis; CHF = congestive heart failure, CoA = coarctation of the aorta. L-TGA = levotransposinon of the great arteriev, MS = mural stenovis. other
abbrevianons as InTable I
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Figure 2. The maturational stages of the ductus artenosu.. (DAl In the
two treatment groups PGE = prostaglandin E,.
Figure 1. The Internal diameters of ductus artenosi (DAl at the pulmonary
and aortic ends 111 the two groups are depicted in circles. Bars represent
mean value, for each group. NS = nonsignificant: PGE = prostaglandin
E,.
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control group (1.40 ± 0.46 mm) (p <0.05) (Fig. I). The
mean internal diameter at the aortic end (Fig. I) was also
greater in the prostaglandin E 1 group (3.70 ± 0.47 mm)
than in the control group (2.74 ± 0.62 mm), but this dif-
ference was not statistically significant.
The ductus arteriosi in the prostaglandin E, group were
significantly more immature than those in the control group
(Fig. 2). The mean maturational stage was 1.67 ± 0.30
for the prostaglandin E 1 group and 3.00 ± 0.29 for the
control group (p < 0.0025). Most of the ductus arteriosi
from the prostaglandin E 1 group were in stage I or 2 while
most from the control group were in stage 3 or 4. The ductus
of one patient from the prostaglandin E, group and two
patients from the control group were in stage 3a and were
considered to be persistent ductus arteriosi.
Histopathologic findings. On microscopic examina-
tion, the ductus arteriosus of two patients in the prosta-
glandin E I group and two patients in the control group
had medial or adventitial hemorrhage or thrombosis of the
ductus (Tables I and 2). None of the ductus arteriosi had
•
•
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*We did not include the 13 patients who died after the age of 20 days
In the study for the following reasons:
I. Five patients died at home. at age 4. 6. 7 and 16 weeks and 2 years.
respectively. and autopsies were not performed.
2. Five patients died after corrective surgery at 4, 5, 6. 14 and 15
months of age and the ductus arteriosus was not patent at a preop-
eranve catheterizalion In any patient.
3. One patient died of sepsis associated with the DiGeorge syndrome
at 4 months. He had correction of Interrupted aortic arch In the
newborn period, at which time the ductus was divided.
4. One patient died of cerebral vascular accident at the age of 8 months
and his ductus was not patent.
5. One patient died of multiple congerutal anomalies at 6 weeks and
had a widely patent ductus which was considered to be a patholog-
ically persistent patent ductus arteriosus. He was not Included In the
study because at his age of 6 weeks, he was much older than any of
the control group patients, whose ages were 3 to 14 days
Results
Gross findings. Grossly, no abnormalities of the duc-
tus arteriosus were found in any heart in either the prosta-
glandin E 1 or the control group. The mean length (± stan-
dard error of the mean) of the ductus arteriosus was somewhat
greater in the prostaglandin E I group (7.43 ± 1.06 mm)
than in the control group (6.07 ± 0.69 mm), but this dif-
ference was not statistically significant. The mean internal
diameter at the pulmonary end was significantly greater in
the prostaglandin E 1 group (2.82 ± 0.58 mm) than in the
Morphologic and histopathologic studies. The gross mor-
phologic and the histopathologic features of the 22 specimens (12
from the prostaglandin E, group and 10 from the control group)
were studied. The intact heart and lungs from each patient had
been preserved in formalin. The length and internal diameters of
the ductus arteriosus were measured at both the pulmonary and
aortic ends. Cross sections of the ductus arteriosus at its midportion
from each heart were examined histologically after staining sec-
tions with hematoxylin-eosin and by the Movat (pentachrome)
technique. Histologic sections from each ductus were examined
without knowledge of the clinical information. The stage of the
maturation was determined and any histopathologic abnormalities
were recorded. Interobserver discrepancies were resolved by re-
view and consensus. We utihzed the classification of maturational
stage of the ductus arteriosus proposed by Gittenberger-de Groot
(15,16), in which stage I is the most immature stage of devel-
opment and stage 4 represents functional closure; stage 3a is the
usual persistent patent ductus arteriosus. Statistical analysis of
differences between the two groups was done by Student's t test;
probability (p) values of :s0.05 were considered Significant.
Follow-up studies*. Of the 49 patients who received prosta-
glandin E, and survived the neonatal period, 28 underwent repeat
cardiac catheterization and angiography from 3 to 23 months (mean
5) after prostaglandin E1 therapy. These cineangiograms were ex-
amined to ascertain patency of the ductus arteriosus and any ab-
normality such as aneurysm, dilation and calcification. The hos-
pital and the clime charts of 36 patients who had been followed
up during the study period ending December 1980 were reviewed;
the follow-up period for these records ranged from 6 to 33 months
(mean 20).
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other significant pathologic abnormalities of interruption of
the internal elastic lamina, intimal laceration, polymor-
phonuclear leukocyte infiltration or medial interruption. Me-
dial edema was seen in six patients (50%) from the prosta-
glandin E) group and in three patients (30%) from the control
group.
Follow-up. None of the 28 follow-up angiograms dem-
onstrated any abnormality in the region of the ductus ar-
teriosus. All but one of the ductus arteriosi had either spon-
taneously closed or been surgically ligated. Of the 36 patients
who received prostaglandin E) in the neonatal period and
have been followed up to 33 months (mean duration of
follow-up 20 months), none demonstrated any clinical signs
or symptoms that could be ascribed to a known side effect
of prostaglandin E).
Discussion
Since the initial reports (1,2) of prostaglandin E) use in
human neonates with ductus-dependent congenital heart de-
fects, its clinical use and side effects have been described
by several investigators (17,18). In most instances, prosta-
glandin E) has been used for a short period of time while
the patient was awaiting surgery or clinical improvement
from decreasing pulmonary vascular resistance in the neo-
natal period. Clinically observed side effects usually have
been transient and dose-related with short-term use of pro-
staglandin E] (3,17). Recently, successful long-term admin-
istration of prostaglandin E), either intravenously (19-22)
or orally (23,24), has been reported.
Histopathology of the ductus after prostaglandin E1
treatment. Gittenberger-de Groot and co-workers (13,14)
reported histopathologic abnormalities in the ductus arte-
riosus after prostaglandin E) administration. The changes
found were medial edema with separation of medial com-
ponents by clear spaces, pathologic interruptions of the in-
ternal elastic lamina, polymorphonuclear leukocyte infiltra-
tion and intimal lacerations. Similar but more severe histologic
changes in a ductus were reported in an infant who had
received prolonged parenteral prostaglandin E) (12). These
observations suggested that after prolonged use of prosta-
glandin E), there may be a real danger of rupture or lac-
eration of the ductus or of contiguous structures at the time
of surgical repair. One patient with interrupted aortic arch
reported by Gittenberger-de Groot (13) died intraoperatively
during attempted repair from rupture of the ductus while it
was being sutured. The mechanism of the apparent dam-
aging effects of prostaglandin E) on the ductus was thought
to be a result of mechanical overstretching of the closing
ductus which was dilated by prostaglandin E 1. Of the 12
ductus arteriosi examined from our prostaglandin E) group,
only 2, in our opinion, showed significant pathologic find-
ings. One of these two patients had medial hemorrhage and
thrombosis of the ductus; in this patient these histologic
findings could be related to the effect of bacterial sepsis
rather than to prostaglandin E\. Medial, as well as adven-
titial, hemorrhagic foci also were found in two patients from
the control group. Edema of the media was seen in 50% of
the prostaglandin E) group and in 30% of the control group.
The histologic interpretation and the significance of the me-
dial edema are not clear.
In our patients, significant histologic abnormalities of the
ductus after prostaglandin E) therapy were uncommon and
did not differ from those in the control group. This finding
is in contrast to prior reports (12-14) of deleterious effects
of prostaglandin E) on ductal morphology. The difference
may be related to the duration of prostaglandin E) admin-
istration; in our patients the mean time was 18 hours in
comparison with 37 hours (13), 47 hours (14) and 39 days
(12).
The lengths ofthe ductus arteriosi from the prostaglandin
E , group were similar to those reported by Gittenberger-de
Groot et al. (13) except in two instances in the prostaglandin
E 1 group in which the lengths were unusually long. We
measured the internal diameter of the ductus rather than the
external diameter because a ductus with a large external
diameter often exhibits functional closure with an obliterated
lumen. Ductus arteriosi from the prostaglandin E\ group
had a larger internal diameter than did those of the control
group, particularly at the pulmonary end. The significantly
larger internal diameter at the aortic end compared with the
pulmonary end supports the concept that closure of the duc-
tus starts at the pulmonary end.
Role of prostaglandin E1 in ductal maturation.
Patency of the fetal ductus arteriosus is now regarded as an
active state sustained by continuous intramural production
of prostaglandin, most importantly prostaglandin E) (25).
The greater incidence of immaturity of the ductus arteriosi
in the patients receiving prostaglandin E) suggests that this
drug delays the normal postnatal maturation and involutional
processes. After withdrawal of the drug, it appears that the
ductus undergoes normal closure even after long periods of
prostaglandin E) treatment (23,24). The phenomenon of
delayed maturation of the ductus treated with prostaglandin
E) was observed by Gittenberger-de Groot et al. (14), who
found that only one of nine ductus arteriosi treated with
prostaglandin E) showed advanced stages of ductal maturation.
Significance of pathologic findings. As suggested pre-
viously, the pathologic changes, with the exception of me-
dial edema observed in two cases in the prostaglandin E I
group, might have resulted from this drug or from other
clinical conditions that led to death. We believe the latter
to be more likely because these pathologic findings were
observed with the same frequency in patients in the control
group who were subjected to similar degrees of hypoxic and
metabolic insults. The medial edema in 50% of the prosta-
glandin E) group in contrast to its finding in 30% of the
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control group might be related to prostaglandin E" which
increases vascular permeability. The possibility exists that
the adverse morphologic effects observed by others after
long-term administration of prostaglandin E 1 could be caused
by the underlying hypoxic insult which necessitated the
long-term use of prostaglandin E,.
We conclude from our present study that prostaglandin
E, administration delays the normal closing process of the
ductus arteriosus and does not have significant deleterious
effects morphologically when administered for short pe-
riods. Further studies including the examination of systemic
and pulmonary vessels (26) are warranted after both short-
and long-term administration of prostaglandin E,. Until fur-
ther information becomes available, it seems advisable to
use prostaglandin E, for as short a duration and at as low
a dose as possible.
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